Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment. (Core HTA 2)

Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment. (Core HTA 2)
Country
Agency
Status
Link
Details on adaptation process
Contact information
Croatia
AAZ
2015
Summary of information from the report for decision makers and website
Mirjana Huic (Mirjana.Huic@aaz.hr)
Spain
ISCII
2016
Summary of information from the report
Iñaki Imaz
This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.